Stockscreener 앱 받기
0.88
6.38%
-0.06
전일 마감가:
$0.94
열려 있는:
$0.92
하루 거래량:
25,005
Relative Volume:
0.40
시가총액:
$31.83M
수익:
-
순이익/손실:
$-8.53M
주가수익비율:
-3.6154
EPS:
-0.2434
순현금흐름:
$-12.75M
1주 성능:
-4.49%
1개월 성능:
-13.73%
6개월 성능:
-23.48%
1년 성능:
-22.81%
1일 변동 폭
$0.8234
$0.99
1주일 범위
$0.7301
$1.02
52주 변동 폭
$0.63
$3.23
Estrella Immunopharma Inc Stock (ESLA) Company Profile
명칭
Estrella Immunopharma Inc
전화
(510) 318-9098
주소
5858 HORTON STREET, SUITE 370, EMERYVILLE
ESLA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
0.88 | 31.83M | 0 | -8.53M | -12.75M | -0.2434 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Buy Rating With a Price Target of $14.00 From CB Capital Partners - BioSpace
Will This Immunotherapy Stock Surge 300%? Analysts See Major Upside in ESLA's Cancer Platform - Stock Titan
Estrella Immunopharma completes first dose cohort in STARLIGHT trial - Yahoo Finance
Sector Update: Health Care -February 21, 2025 at 03:42 pm EST - Marketscreener.com
Estrella Immunopharma Completes First Dose Group in Non-Hodgkin Lymphoma Study - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort In Starlight-1 Trial And Receives Approval To Initiate Higher Dose Cohort - Marketscreener.com
Estrella Immunopharma Completes First Dose Cohort in STARLIGHT-1 Trial and Receives Approval to Initiate Higher Dose Cohort - The Bakersfield Californian
Estrella Immunopharma, Inc. (NASDAQ: ESLA; ESLAW) Receives Buy Rating with a 12-Month Price Target of $16.00 from D. Boral Capital - 01net
Estrella Immunopharma (NASDAQ:ESLA) Now Covered by Analysts at D. Boral Capital - Defense World
Can This Revolutionary T-Cell Platform Transform Blood Cancer Treatment? Analysts Think So - Stock Titan
This aTyr Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Estrella Immunopharma regains Nasdaq compliance - Investing.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Stock Quotes, Forecast and News Summary - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Stock Quotes, Forecast and News Summary - Benzinga
Estrella Immunopharma extends stock sale agreement with White Lion By Investing.com - Investing.com Canada
Estrella Immunopharma faces Nasdaq delisting over equity shortfall - Investing.com
Chengxi Shipyard Co., Ltd. announced that it expects to receive CNY 425 million in funding from China Structural Reform Fund Co., Ltd., China Pacific Property Insurance Co., Ltd., China Life Insurance Company Limited, PICC Property and Casualty Company - Marketscreener.com
Estrella Immunopharma Inc (ESLA) Quarterly 10-Q Report - Quartzy
Spotlight On US Penny Stocks: Estrella Immunopharma And Two Others To Consider - Simply Wall St
Eureka Therapeutics Tackling Advanced Hepatocellular Carcinoma With T-Cell Therapy ECT204 in Phase 1/2 ARYA-3 Clinical Trial - CGTLive™
Estrella Immunopharma Appoints Dr. Cheng Liu as CEO - TipRanks
Decoding Houlihan Lokey Inc (HLI): A Strategic SWOT Insight - Yahoo Finance Australia
Tesla stock hits 52-week low at $0.75 amid market challenges - Investing.com UK
ARMOUR Residential REIT, Inc. Announces November 2024 Dividend Rate per Common Share - Yahoo Finance Australia
Westrock Coffee Company (WEST) Moves 10.8% Higher: Will This Strength Last? - Yahoo Finance Australia
Around the Helix: Cell and Gene Therapy Company Updates – October 9, 2024 - CGTLive™
First Patient Dosed Achieves Complete Response in Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas - CGTLive™
HP Inc. gets hit with downgrade from Citigroup - Yahoo Finance Australia
Estrella Immunopharma Shares Rise on Lymphoma Patient's Treatment Response - MarketWatch
Estrella Immunopharma Achieves Complete Response in First Patient Treated with CD19- Redirected ARTEMIS - Business Wire
Best Income Stocks to Buy for September 25th - Yahoo Finance Australia
Despite selling recently, Dell Technologies Inc. (NYSE:DELL) insiders own 50% stake and recent decline might have cost them - Yahoo Finance Australia
Here is What to Know Beyond Why PayPal Holdings, Inc. (PYPL) is a Trending Stock - Yahoo Finance Australia
Estrella Immunopharma Announces Appointment of Hong Zhang as Chairperson and Board Member - Business Wire
Estrella Immunopharma’s Trial for CD19-Targeted T-cell Therapy EB103 in B-Cell Lymphomas Doses First Patient - CGTLive®
Wall Street today: US stocks trade higher after promising inflation data raises Fed rate cut bets; 3M Co. gains 18.99% - Mint
OS Therapies (AMEX:OSTX) Stock Quotes, Forecast and News Summary - Benzinga
DoorDash’s CFO on the company’s Fortune 500 debut: ‘Our goal wasn’t to build a food delivery business’ - Yahoo Finance Australia
Chemed Corporation to Present at the Jefferies 2024 Global Healthcare Conference - Yahoo Finance Australia
Shift4 Payments Inc (FOUR) Chairman & CEO Jared Isaacman Acquires 39,135 Shares - Yahoo Finance Australia
Why One Stop Systems, Inc. (NASDAQ:OSS) Could Be Worth Watching - Yahoo Finance Australia
Wheels Up Experience Inc (UP) Q1 2024 Earnings Analysis: Challenges and Strategic Adjustments ... - Yahoo Finance Australia
AskBio Evaluates ACTUS-101 Gene Therapy for Late-Onset Pompe Disease - CGTLive™
Laura Franco - Mintz
Allogeneic CD22 CAR Cleared for First-in-Human Trial in B-Cell Malignancies - CGTLive™
Next Big Thing: 3 Biotech Stocks to Watch for Groundbreaking Advances - InvestorPlace
Excision Seeks to Suppress HIV Viral Replication With EBT-101 CRISPR Gene Therapy - CGTLive™
Direct Biologics’ Phase 1 Clinical Trial Seeks to Treat Crohn Disease With Extracellular Vesicles - CGTLive™
Tenaya's Phase 1b MyPeak-1 Trial is Testing the Waters in Gene Therapy for Hypertrophic Cardiomyopathy - CGTLive™
ESLAEstrella Immunopharma Latest Stock News & Market Updates - StockTitan
ESLA Stock Price and Chart — NASDAQ:ESLA - TradingView
Estrella Immunopharma Inc (ESLA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):